{"filing":{"accession_number":"0001129928-26-000041","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"oncy-20260616.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000041/oncy-20260616.htm"},"events":[{"id":11236,"run_id":9854,"accession_number":"0001129928-26-000041","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The disclosure announces a new patent related to manufacturing of pelareorep and updates to the intellectual property portfolio. For a biotech company, patent issuance and IP portfolio strengthening can be material to investors assessing competitive position and product protection, though the filing provides limited detail on the patent's scope or commercial significance. This does not fit neatly into the more specific event categories (not earnings, litigation, impairment, etc.), warranting classification as other_material.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7782,"accession_number":"0001129928-26-000041","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure announces a new patent related to manufacturing of pelareorep and updates to the intellectual property portfolio. For a biotech company, patent issuance and IP portfolio strengthening can be material to investors assessing competitive position and product protection, though the filing provides limited detail on the patent's scope or commercial significance. This does not fit neatly into the more specific event categories (not earnings, litigation, impairment, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T13:06:06.203200+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7782,"accession_number":"0001129928-26-000041","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure announces a new patent related to manufacturing of pelareorep and updates to the intellectual property portfolio. For a biotech company, patent issuance and IP portfolio strengthening can be material to investors assessing competitive position and product protection, though the filing provides limited detail on the patent's scope or commercial significance. This does not fit neatly into the more specific event categories (not earnings, litigation, impairment, etc.), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T13:06:06.203200+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-06-16"}]}